Enteric NK/T Cell Lymphoma-induced Recurrent Perforation in the Intestine: A Case Report.

Ann Ital ChirSep 15, 2026
Case ReportOncology (Medical)GastroenterologyPathology (Anatomic & Clinical)

Jiansen Su, Yixiao Yang, Xinyi Huang et al.

✦ AI-curated · Sources linked

Case in brief

A 31-year-old female presented with abdominal pain and fever, following a previous jejunal perforation diagnosed as an EBV-associated lymphoproliferative disorder. Despite negative biopsy results, imaging confirmed intestinal perforation, leading to emergency surgery. Histopathology revealed ENKTL, confirmed by positive immunohistochemical staining. The patient underwent chemotherapy post-surgery and showed significant improvement over 26 months, with no recurrence.

Diagnostic / clinical pearl

Clinicians should consider primary intestinal NK/T-cell lymphoma in young patients with unexplained gastrointestinal perforation, as its non-specific symptoms can complicate early diagnosis.

Why it matters

This case highlights the importance of repeated biopsies and EBER detection in diagnosing rare malignancies, which can significantly impact treatment outcomes.

Source

PubMed · PMID 42755319

Published in Ann Ital Chir. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.